C ell nuclei carry an abundance of nuclear proteins and the majority of the cell's genetic content. Molecular changes in the levels of nucleic acids and chromatin and altered expression patterns of nuclear matrix proteins are highly relevant to malignant progression 1 . Recent studies have found that higher levels of nucleic acids (aggregates of chromatins) are present in various cancers [1] [2] [3] [4] , indicating the potential use of nucleic acids for cancer screening and monitoring. In addition, the overexpression of specific protein biomarkers, such as epidermal growth factor receptor (EGFR) [5] [6] [7] , cellular tumour antigen p53 8 , cell regulator protein Bcl-2 9 , and cell division cycle protein CDK-1 10 , in cell nuclei is of particular prognostic significance 11 , as they are highly correlated with patient survival rate and response to chemotherapy and radiotherapy in many types of cancers (such as lung cancer 6 , triple-negative breast cancer 12 , colorectal cancer 9, 13 , ameloblastoma 14 , ovarian cancer 15 , and gastric cancer 16 ). The detection and evaluation of those nuclear biomarkers (nucleic acids and proteins) in human tissues will help better understand the signalling pathway in cancers and, more importantly, provide critical information for early-stage cancer diagnosis, prognosis and malignant transformation, as well as for the efficacy of anticancer therapies [17] [18] [19] [20] [21] .
So far, the evaluation of microscopic histopathology slides by pathologists remains the golden standard for cancer diagnosis, which is based mainly on the morphological assessment of cell nuclei in tissues using heamatoxylin and eosin (H&E) staining 22, 23 . However, due to the lack of quantitative analysis capability, this method is highly subjective, and even the best-characterized histopathological features receive only modest agreement among experienced pathologists, which may result in misdiagnosis and poor treatment management 24 . This issue becomes particularly serious and challenging in early-stage cancers 25 .
Meanwhile, for cancer prognosis and guided therapy, immunohistochemistry (IHC) is widely used to analyse specific antigens, especially prognostic and predicative biomarkers 26, 27 . IHC relies on colorimetric detection to identify the location of a given proteomic biomarker within a tissue. While simple, IHC performs poorly in distinguishing biomarkers in nuclei from their surrounding background due to the nonlinear optical effect and low dynamic range 20 (an example is given in Supplementary Fig. 1 ). Consequently, the cells having overexpressed nuclear proteomic biomarkers may be misdiagnosed. This problem is exacerbated when multiple targets in a nucleus are to be analysed. Compared to colorimetric detection, immunofluorescence (IF) uses different fluorescent labels to tag different biomarkers, thus resulting in improved contrast and multiplexing capability over IHC 21, 28 . However, despite elevated biomarker concentrations in the nuclei for cancers at an advanced stage, the fluorescence signals from the nuclear biomarkers are often embedded in a large patch of background fluorescence from cytoplasm that may also express the same biomarkers ( Supplementary  Fig. 1 ). In addition, IF suffers significantly from the broad emission spectra of fluorophores, which poses yet another hurdle to distinguish the biomarkers from nearby features with similar emission wavelengths. Therefore, it becomes challenging to accurately identify the nuclei that have biomarker expression and to precisely pinpoint the exact biomarker locations inside the nuclei, which may cause significant distortion and subsequent misinterpretation of the characterization of the cancer tissue 29 .
Recently, biolasers in which the laser emission is used as the sensing signal have been developed [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . In comparison with fluorescence-based detection, laser emission has narrow linewidth, threshold behaviour, high intensity and high sensitivity to biomolecular/cellular changes. Therefore, biolasers may provide a new bioanalytical tool that complements traditional fluorescent
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Detection of nuclear biomarkers, such as nucleic acids and nuclear proteins, is critical for early-stage cancer diagnosis and prognosis. Conventional methods relying on morphological assessment of cell nuclei in histopathology slides may be subjective, whereas colorimetric immunohistochemical and fluorescence-based imaging are limited by strong light absorption, broad emission bands and low contrast. Here, we describe the development and use of a scanning laser-emission-based microscope that maps lasing emissions from nuclear biomarkers in human tissues. Forty-one tissue samples from 35 patients labelled with site-specific and biomarker-specific antibody-conjugated dyes were sandwiched in a Fabry-Pérot microcavity while an excitation laser beam built a laser-emission image. We observed multiple subcellular lasing emissions from cancer cell nuclei, with a threshold of tens of μ J mm −2 , submicrometre resolution (< 700 nm), and a lasing band in the few-nanometre range. Different lasing thresholds of nuclei in cancer and normal tissues enabled the identification and multiplexed detection of nuclear proteomic biomarkers, with high sensitivity for early-stage cancer diagnosis. Laser-emission-based cancer screening and immunodiagnosis might find use in precision medicine and facilitate research in cell biology.
techniques. In one of the biolaser techniques, bio-species (such as biomolecules, cells and tissues) are placed inside a Fabry-Pérot (FP) cavity, and the laser characteristics such as lasing wavelength, threshold and intensity are modulated either passively (that is, biospecies are not labelled and the gain media are outside those biospecies) [30] [31] [32] or actively (bio-species are labelled with fluorophores that serve as the laser gain media) 33, 45, 46 . However, so far, no studies have been carried out to use biolasers to identify and detect specific biomarkers within cells/tissues, in particular, using actual patients' samples. Whether biolasers can truly provide bioanalytical capabilities remains to be shown.
Here, we report the use of a scanning laser-emission-based microscope (LEM) for improved tumuor-tissue characterization based on the earlier development of a tissue laser platform 45 . Successful mapping of the lasing emissions from nuclear biomarkers (such as nucleic acids and/or specific antigens) were achieved in human tissues with a subcellular and sub micrometre resolution (< 700 nm) and a lasing threshold on the order of tens of μ J mm −2 . Figure 1a illustrates the concept of the LEM, in which a tissue labelled with site-specific fluorophores (such as nucleic acid probes) and/or antibody-conjugated fluorophores is sandwiched inside an FP microcavity formed by two mirrors. The fluorophores serve as the laser gain medium, which are designed to respond to intracellular binding and intratissue activities, thus generating the sensing signal in the form of laser emission. A 2D scanning stage was integrated to map the tissue and construct images by scanning the pump beam across the whole tissue. As illustrated in Fig. 1b , while fluorescence (top) from a nucleus usually provides a 'spatially blurred' signal (which covers a large area with a low spatial resolution and a low contrast between the sites with high and low biomarker expressions), laser emission (bottom) offers distinct advantages due to its high intensity/sensitivity 34, 35, 38, 39 , high fluorescence background suppression (for high contrast imaging) 43, 45 , high spatial resolution 35, 47 , high spectral resolution (for highly multiplexed detection) and unique threshold behaviour (to selectively switch on/off specific laser emission signals ( Fig. 1c,d) 48 .
In particular, we show lasing with lung and colon cancer tissues in a total of 41 biopsy samples from 35 patients (more than 100 tissue sections). Nucleic acid dye, YO-PRO-1 iodide (YOPRO) and several antibodies (such as anti-EGFR, mutant p53 and Bcl-2) conjugated with fluorescein isothiocyanate (FITC) were used to analyse nucleic acids and the proteomic biomarkers within the nuclei, respectively. We demonstrate that the LEM is able to clearly distinguish between cancer and normal tissues, and diagnose earlystage lung cancer tissues with a sensitivity of 97.5%. Tumour tissues with and without nuclear proteomic biomarkers can be quantified due to vastly different lasing thresholds resulting from the different nuclear expressions of the biomarkers. Furthermore, we show the wavelength-multiplexed immuno-lasing capability of the LEM. Dual lasing emissions were achieved to signify the colocalization of nucleic acid and nuclear proteomic biomarkers. We envision that this study will provide an imaging tool complementary to H&E, Here, only one antibody is shown; however, multiple targeted antibodies/fluorophores can be used. b, A comparison between the traditional fluorescence emission (top) and the 'star-like' laser emission (bottom) from a single nucleus. c, Left: output intensity of laser emission as a function of pump intensity. P c , lasing threshold of cancer cell lasing; P n , lasing threshold of normal cell lasing. A higher/lower nucleic acid concentration leads to a lower/higher lasing threshold. Right: laser emission (LE, red solid line) has a much narrower emission profile than traditional fluorescence (FL, blue dashed line). The dotted yellow lines indicate the correspondence in laser emission intensity for the various peaks across the two graphs. d, Fluorescence emission is detected in both normal and cancer cell nuclei, whereas laser emission can be detected only in cancer cell nuclei when pump energy density is set between P c and P n .
results
The detailed description of mirror fabrication/characterization, FP cavity assembly and the LEM setup can be found in the Methods and Supplementary Fig. 2 . Human tissue sections (cancerous and normal) were prepared under the same conditions at a thickness of 15 μ m, and were all labelled with either YOPRO to target nucleic acids inside cells or FITC-conjugated antibodies that bind specifically to EGFR, mutant p53 or Bcl-2, which can be expressed on the cell membranes, cytoplasmic organelles (endoplasmic reticulum, Golgi and endosome) and nuclei. It should be noted that these antibodies are not only specific to the cell nuclei; however, clinical studies have identified the presence of such biomarkers in the nuclei as a critical indicator in determining the patients' survival rate and prognosis 13, 18 . Details of sample preparation and staining procedures can be found in the Methods.
Lasing in tissues with nucleic acid probes. We began with the lung tissues labelled with YOPRO alone. Figure 2a ,b shows the lasing spectra of cancerous and normal lung tissues under various pump energy densities when 0.5 mM YOPRO solution was used to label the tissues (H&E images in Supplementary Fig. 3 ). A sharp lasing peak emerges around 547 nm. As a control experiment (not shown), no lasing was observed with pure YOPRO solution (without any tissue) at 0.5 mM, which is expected, as YOPRO has virtually no emission in the absence of nucleic acids. The spectrally integrated laser emission versus pump energy density extracted from Fig. 2a ,b are presented in Fig. 2c , from which the lasing threshold of cancer and normal tissue are derived to be 21 μ J mm −2 and 32 μ J mm −2 , respectively. Furthermore, we investigated the dependence of the lasing threshold on the concentration of the YOPRO solution used to stain the tissues at a fixed resonator length (15 µ m) for both cancer and normal tissues ( Fig. 2d ). When the YOPRO solution concentration decreases from 0.5 mM to 0.05 mM, the effective YOPRO concentration within the nucleus is expected to decrease accordingly, which leads to a drastic increase in the lasing threshold, especially for YOPRO concentrations below 0.25 mM. For all YOPRO concentrations, we find that the lasing thresholds for cancer tissues are consistently lower than those of normal tissues, which is attributed to the higher amount of nuclear chromatin (and hence higher YOPRO concentrations) inside cancer cells (due to higher DNA replication activity) 1, 49, 50 . In addition, we noticed that the lasing emissions remain in single-mode operation even at a pump energy density significantly higher than the respective lasing threshold ( Fig. 2a,b ). The full-width at half-maximum (FWHM) of the lasing emission is only 0.16 nm, limited by the spectrometer resolution. Such a single-mode lasing emission band is > 100× narrower than that for the corresponding fluorescence, thus enabling highly wavelength-multiplexed detection. Although the YOPRO-stained tissue can support multi-mode lasing operation Three individual measurements were taken for each concentration at different sites, as presented individually with green and red points. e, A confocal fluorescence image of a lung cancer nucleus (shown in green). f,g, CCD images of the laser output from a nucleus in a lung cancer tissue around (24 μ J mm −2 ; f) and far above (50 μ J mm −2 ; g) the lasing threshold. The images show sharp lasing stars within the nucleus, and significantly suppressed background fluorescence. h, A confocal image of a normal lung nucleus (in green). i,j, CCD images of the laser output from a nucleus in a normal lung tissue below (24 μ J mm −2 ; i) and above (50 μ J mm −2 ; j) the lasing threshold. Note that e,h and g,j were taken from the same piece of tissue, but the images do not show exactly the same cells. All the tissues in a-j were stained with YOPRO (0.5 mM in bulk staining solution) under the same preparation conditions. The dashed squares in g,j show the laser pump beam area in the LEM. Scale bars, 5 μ m. The corresponding H&E images of the cancer tissues and normal tissues are provided in Supplementary Fig. 3 .
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at an extremely high pump energy density (5× the threshold) ( Supplementary Fig. 4 ), the overall lasing band is still less than 10 nm wide, attesting to the intrinsic narrow gain profile for YOPRO, despite a wide fluorescence band. Figure 2e shows the confocal fluorescence microscopy image of a nucleus in a cancer cell from the lung cancer tissue. Due to the low contrast of the fluorescence emission within the nucleus, we are unable to extract the exact locations that have high nucleic acid concentrations. However, as visualized by CCD images (Fig. 2f,g) , multiple sharp laser emissions with distinct and strong output against the surrounding background ('lasing stars') are visible at specific sites with the highest abundance of nucleic acids. With increased pump energy density, more sites with a slightly lower abundance of nucleic acids start to lase (see Supplementary Video 1). Note that there may be fluorescence background emitting from the places that have relatively low concentrations of nucleic acids and therefore are unable to generate laser emission. However, such fluorescence is completely blocked by the top mirror that has > 99.8 % reflectivity. Similarly, we also carried out a series of parallel experiments using a normal lung tissue ( Fig. 2h -j) and observed the same phenomena as in Fig. 2f ,g, except that the lasing stars start to emerge at a higher pump energy density and, at a given pump energy density, fewer lasing stars are observed, both of which reflect the lower abundance of nucleic acids in a normal tissue, as discussed in Fig. 2d .
Characterization of the LEM. To further characterize those lasing stars, we plot the laser emission profile of a single lasing star from the lung cancer tissue captured on the CCD (Fig. 3a) . The FWHM is measured to be approximately 678 nm, providing a submicrometre and subcellular optical resolution (defined by the FWHM). Two adjacent lasing stars separated by only 1.3 μ m can be well resolved ( Fig. 3b) . A comparison between bright-field, fluorescence and laser-emission images using identical cancer cells is shown in Supplementary Fig. 5 , showing high spatial resolution and high contrast of the LEM, which is due mainly to the background suppression mechanism in the LEM (the background here is defined as the noise or low-level signals within the cell nuclei). The insets in Fig. 3c -f illustrate how subcellular lasing stars emerge progressively from a single to multiple lasing stars within the same pumping beam spot when the pump energy density increases gradually. The spectral analysis in Fig. 3c -f suggests that those lasing stars are independent of each other. Each of them is in single lasing mode operation, but may have slightly different lasing wavelengths due possibly to different local environments (such as nucleus thickness, refractive index, gain distribution, and so on). As exemplified in Fig. 3c -f, at a relatively low pump energy density, only those sites having the highest analyte concentration can lase. With the increased pump energy density, lasing from multiple sites can be observed. Conversely, multiple lasing sites can be 'turned off ' , down to a single lasing site, by decreasing the pump energy density (see Supplementary Video 1), thus signifying the repeatability and controllability of those lasing stars.
Furthermore, spatial analysis shows that those lasing stars are the lowest order (0,0) Ince-Gaussian mode 51, 52 , which is due largely to the localization of nucleic acids (and hence the YOPRO). To validate this, we conducted a series of experiments by staining lung normal/cancer tissues with FITC (a non-specific dye) for comparison ( Supplementary Fig. 6 ). Despite the refractive index differences, similar lasing modes (generally higher-order Ince-Gaussian modes) Intensity (a.u.) The yellow square identifies the location of two lasing stars within the tissue. The intensity profile along the dotted line shows two well-resolved peaks. The smallest resolvable distance between two laser emissions is estimated to be better than 1 μ m. c-f, Lasing spectra of independent subcellular lasers within the same focal beam spot by increasing the pump energy density from 20 μ J mm −2 (c) to 30 μ J mm −2 (d), 40 μ J mm −2 (e) and 50 μ J mm −2 (f). The insets show the CCD images of corresponding laser emissions: c is an example of a single lasing star; d is an example of two independent lasing stars with different lasing thresholds; e is an example of three independent lasing stars with different lasing thresholds; and f is an example of multiple independent lasing stars emerging simultaneously at a high pump energy density. Note that the slight increase in the background emission beyond 560 nm in c-e is due to the fluorescence leaking out of the FP cavity due to the reduced reflectivity of the dielectric mirror (see Supplementary Fig. 2 for details). Numerical aperture (NA) = 0.42. All scale bars, 5 μ m.
were observed for both normal and cancer cells ( Supplementary  Fig. 6d,e ), suggesting that FITC is equally distributed throughout the cell. In contrast, multiple independent lasing modes (lasing stars) can be observed in cells labelled with YOPRO. The significant difference between FITC and YOPRO in Supplementary Fig. 6 supports the hypothesis that the lasing star is caused by the localization (concentration) effect of nucleic acids (and hence dyes). Consequently, the results in Fig. 3 provide an alternative method to quantify the analyte concentration in tissues (or cells) with a submicrometre spatial resolution by increasing the pump energy density. The image for each pump energy density can be recorded so that the distribution of analyte relative concentration can be mapped and a histogram of the sites having different levels of analyte concentrations can be built, thus enabling more detailed characterization of tissues and cells.
Lasing thresholds of cancer/normal tissue biopsy. According to the results in Fig. 2d , the lasing thresholds for the cancer cell nuclei are generally lower than those for the normal cell nuclei. In particular, Fig. 2d shows that the binding of YOPRO to nuclear acids starts to saturate beyond 0.1 mM in cancer tissues. Thus, the largest difference in lasing threshold is achieved at 0.1 mM, which can be explored to distinguish between cancer and normal tissues. We investigated systemically the lasing thresholds of 14 patients' biopsies (including 10 sets of normal/cancer lung tissue; H&E images are given in Supplementary Fig. 7 ), all of which were stained with 0.1 mM YOPRO ( Fig. 4 ). First, we present the statistics of lasing thresholds based on the 6 pairs of lung cancer tissues and normal lung tissues from the same patients (P1-P6) in Fig. 4a ,b. Two types of non-small-cell lung cancer, adenocarcinoma and squamous cell carcinoma ( Fig. 4c , for example), were investigated. At least 20 cells were randomly selected and measured within each tumour/normal tissue region for each patient. Interestingly, all cancer cells exhibit consistently a narrow lasing threshold range around 20 μ J mm −2 . By contrast, the normal cells have a much wider threshold range, varying from 30 μ J mm −2 to 180 μ J mm −2 . Next, we investigated the lasing thresholds based on 4 pairs of cancer and normal tissue from 8 different patients (4 normal: P7-P10; and 4 cancer: P11-P14) to examine sample-to-sample variations. Similar results of lasing thresholds were observed in Fig. 4d ,e, and both P values of twosample t-tests between normal and tumour cells from the same/different patients are < 0.005. The histogram of the lasing thresholds (N = 472 cells) in Fig. 4f , extracted from Fig. 4a,b ,d,e, shows clearly a cutoff threshold around 30 μ J mm −2 between the normal and cancer cells. As discussed previously, the stark difference in the lasing threshold is attributable to the different nucleic acid concentrations within cell nuclei 53 . As shown in the fluorescence images in the inset of Fig. 4f , normal cells Lung cancer screening with scanning LEM. Based on the statistic results in Fig. 4f , we employed the LEM to distinguish the cancer and normal tissues by mapping the laser emissions from nuclei in both cancer and normal tissues from 3 individual patients ( Fig. 5 ; P15, P16 and P17; see Supplementary Fig. 8 for H&E images). 
For each patient, 5 tissue sections (for both cancer and normal tissues) were scanned with the LEM over a field-of-view of 150 × 150 μ m under a fixed pump energy density of 30 μ J mm −2 , as shown in Fig. 5a -c. It is obvious that none or only a few lasing stars appeared in normal tissue sections. In contrast, a large number of lasing stars were observed in cancer tissue sections, where isolated individual lasing stars and clusters of lasing stars were both present, as the pump energy density is above the lasing threshold for cancer cells. Quantitative analyses of the number of lasing cells using the LEM results in Fig. 5a -c are plotted in Fig. 5d -f (note that a lasing cell is defined as a cell that has one or more lasing stars). Statistically significant differences between the cancer and normal tissues were achieved (P < 0.005 with two-sample t-test), demonstrating the superior contrast and screening capability of the LEM. As a comparison, we scanned the same tissues with confocal fluorescence microscopy ( Supplementary Fig. 9 ). Further analyses of the same confocal fluorescence images show that the fluorescence of the cancer and normal cells is very similar in intensity and spatial distribution ( Supplementary Fig. 10 ). The results in Supplementary Figs. 9 and 10 suggest that confocal fluorescence microscopy is unable to distinguish/quantify cancer and normal tissues by nucleic acid expression by simply using fluorescence intensity distribution. In Supplementary Figs. 9 and 10 , cancer and normal tissues can still be distinguished by the cell sizes/morphologies; however, for morphology-based tissue evaluation, H&E rather than fluorescence microscopy is the golden standard. Later in Fig. 6 and Supplementary  Fig. 11 , we tested the LEM with early-stage cancer tissues, where cancer/normal tissues cannot be distinguished by the cell sizes/ morphologies. In comparison with histopathology analysis, which is based on morphological assessment of cells and tissues, the LEM method for mapping the lasing emissions from nuclei may provide a simpler, more systematic and more quantitative tool to complement the traditional H&E method in tissue characterization.
To establish the sensitivity and specificity of the LEM technique, we randomly selected 8 cancer patients and performed the LEM on normal and cancer tissues. By using the same experimental condition and quantification methods as in Fig. 5 , five tissue sections (frames) were scanned for each patient for both cancer tissue and normal tissue (a total of 80 frames, N = 80). The histogram of the number of the lasing cells per frame for normal tissues and cancer tissuess are plotted in Fig. 5g,h . Based on the number of lasing cells per frame, we generate the receiver operation characteristic (ROC) 
curve in Fig. 5i , which has an area under the curve of 0.998. We found that the optimal threshold to identify a cancer tissue is 5 lasing cells per frame, which corresponds to a sensitivity of 97.5%. The threshold can be adjusted for higher sensitivity or higher specificity. Using the threshold established above, we further demonstrated an important application of the LEM by examining early-stage lung cancer tissues, which is regarded as the most critical and challenging task in clinical histopathology. For this study, we used three samples from three patients diagnosed with early-stage lung cancer (in-progress lung cancer; see Fig. 6a -c for the H&E images). The confocal fluorescence images are provided in Supplementary  Fig. 11 . Normal cells, cancer cells and in-progress cancer cells are clearly mixed within the whole tissue, making it very difficult to identify and differentiate according to cell morphology and/or fluorescence intensity. By contrast, by using the LEM, cancer cells can be unambiguously identified within the tissue with high contrast. For each patient, five sections were scanned with the LEM under a fixed pump energy density of 30 μ J mm −2 (Fig. 6d-f ). Quantitative analyses of the number of lasing cells using the LEM are also plotted in Fig. 6g -i. All three tissues are identified as cancer tissues since all frames have more than five lasing cells.
Multiplexed detection with immuno-lasing in lung cancer tissues.
Moving a step forward, we aim to improve the prognostic prediction of cancer patients by demonstrating immunodiagnosis capability of the LEM. We studied the lasing emission using anti-EGFR antibody conjugated with FITC (anti-EGFR-FITC) to target nuclear EGFR (n-EGFR) expressed in the same lung cancer tissue used in Fig. 2 (Fig. 7) . Similar to the YOPRO setting in Fig. 2a, Fig. 7a shows single-mode lasing emission with an FWHM of about 0.16 nm when the pump energy density is slightly above the threshold. Even though the second mode emerges with the increased pump energy density, the lasing band is only about 8 nm, much narrower than the corresponding fluorescence band (> 60 nm; Supplementary Fig. 12 ). The spectrally integrated laser emission versus pump energy density extracted from Fig. 7a is presented in Fig. 7b , showing a lasing threshold of approximately 67 μ J mm −2 . We further investigated 10 samples from 5 lung cancer patients with a positive response for nuclear EGFR (patients P21-P25; details in Supplementary Fig. 13 ). The measured lasing thresholds are plotted in Fig. 7c . The variation in the lasing threshold is caused by the different degrees of EGFR expression (hence FITC concentration) in each cell nucleus. For comparison, it is difficult for conventional IF microscopy (Fig. 7d ) to pinpoint the exact locations within the nucleus that have high EGFR concentrations. Similar to the YOPRO lasing case studied previously, significant improvement is achieved with the laser emission in the imaging contrast and capability to locate the spots of high EGFR concentrations with a submicrometre resolution (Fig. 7e,f) .
With the subcellular lasing from n-EGFR achieved in Fig. 7 , we applied the LEM to distinguish the lung tissues with and without n-EGFR in Fig. 8 . We prepared two types of lung cancer tissues: adenocarcinoma with and without n-EGFR (tissue types 1 and 2, respectively). Both types 1 and 2 are well characterized, and were verified by pathologists (see Methods and Supplementary Fig. 13 ). The exemplary lasing spectra of type 1 (red curve) and 2 (blue curve) tissues when stained with anti-EGFR-FITC are shown in Fig. 8a . As expected, laser emission at 537 nm is obtained in tissue 1 with a pump energy density of 80 μ J mm −2 ; however, no lasing from tissue 2 can be observed from the entire tissue when pumped with the same energy density. This result indicates that cells having 
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EGFR expression only on the membranes or other cytoplasmic organelles are not capable of providing sufficient gain to lase owing to relatively low abundance of EGFR (and hence FITC). To validate the above experiments, we examined a total of 12 human patients with 3 tissue sections from each patient, including 6 lung cancer patients with n-EGFR and 6 patients without n-EGFR (3 normal and 3 lung cancer diagnosed without n-EGFR). Details of the 12 patients are provided in Supplementary Fig. 13 , labelled as patients P21-P32. Among all the 6 patients with n-EGFR, 5 showed positive lasing emissions (P21-P25). For all normal patients (P30-P32) and those having lung cancer but without n-EGFR (P27-P29), none showed lasing emissions from anti-EGFR-FITC. The statistic results are plotted in Fig. 8b . The corresponding IHC images of both types of tissues in Fig. 8b (right column) confirm that type 1 tissue has a significant amount of EGFR within most cell nuclei, whereas type 2 tissue does not have any EGFR expression within the cell nuclei (but does have EGFR expressed on the cell membrane).
To further confirm that FITC lasing is from only the expression of EGFR in the nucleus, colocalization of EGFR and nucleus lasing signals from subcellular locations is critical, as it not only verifies the presence of n-EGFR in a nucleus but also makes it easier for computer-aided imaging processing in the future. To demonstrate colocalization, both type 1 and type 2 tissues were dual stained with YOPRO and anti-EGFR-FITC (see Methods). It is apparent that the subcellular locations cannot be clearly determined by their fluorescence, nor can the EGFR expressions in nucleus and cytoplasm be distinguished, due to the huge spectral overlap between YOPRO and FITC ( Supplementary Fig. 12 ). In contrast, lasing signals of the two dyes can be observed and distinguished spectrally for type 1 tissue. As shown in Fig. 8c , two sharp lasing peaks appear at 537 nm and 547 nm when the tissue was pumped at the nucleus, which is the evidence of dual lasing from both EGFR and nucleic acids. The inset in Fig. 8c shows a CCD image, which confirms the presence of EGFR in the nucleus. Note that since the lasing threshold of FITC is much higher than that of YOPRO, the lasing intensity from FITC is lower than that from YOPRO under the same pump energy density. Also, note that even at higher pump energy densities at which higher-order modes may emerge, the lasing spectra of YOPRO and FITC can still be distinguished due to their very narrow emission bands ( Supplementary Fig. 4 ). As a negative control, for type 2 tissue (Fig. 8d ) only lasing spectrum from YOPRO was obtained when the tissue was pumped at the nucleus and no lasing signal from EGFR was observed, indicating that no (or very little) EGFR exists in the nucleus.
Immuno-lasing for nuclear biomarker detection in colorectal cancer tissues.
Finally, we applied the LEM to other types of tissues and proteomic biomarkers to validate its broad use. In Supplementary  Fig. 14 we examined three different important cancer biomarkers (EGFR, p53 and Bcl-2) in human colon cancer tissues. For the purpose of tissue characterization, Supplementary Fig. 14a -c presents the IHC and confocal IF images of colorectal cancer tissues labelled with the corresponding antibodies (that is, anti-EGFR, anti-mutant p53 and anti-Bcl-2), showing a high level of EGFR, p53 and Bcl-2 in the nuclei of the respective tissues. Similarly to the procedures used previously, the lasing emissions from those colon tissues labelled with anti-EGFR-FITC, anti-mutant p53-FITC and anti-Bcl-2-FITC Supplementary Fig. 13 . Top image: bright-field IHC image of a human lung cancer tissue with n-EGFR (tissue type 1). Bottom image: bright-field IHC of a human lung cancer tissue without n-EGFR overexpression (tissue type 2). c, Lasing spectra of a type 1 tissue (positive for nuclear EGFR; green circle) dual-stained with YOPRO and EGFR-anti-FITC. The laser was focused on a single nucleus within the lung cancer tissue. The pump energy density was set above the threshold for both YOPRO and FITC under a single excitation wavelength. The inset CCD image shows n-EGFR laser emission, which indicates that EGFR colocalizes with the nucleus. d, Lasing spectra of a type 2 tissue (negative for nuclear EGFR; blue circle) dual-stained with YOPRO and anti-EGFR-FITC. The laser was focused on a single nucleus within the lung cancer tissue. Note that the slight increase in the background emission beyond 550 nm in a,c is due to the fluorescence leaking out of the FP cavity due to the reduced reflectivity of the dielectric mirror (see Supplementary Fig. 2 ). Scale bars, 20 μ m.
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were achieved in Supplementary Fig. 14d-f , when the nuclei were pumped. Our results show that lasing is achieved when a high level of biomarker is present within the nuclei, which can be used for immunodiagnosis of various nuclear biomarkers. Despite the existence of multiple lasing peaks at the high pump energy density, the laser emission band is still approximately only 5 nm, showing the potential capability of multiplexed detection. The corresponding lasing threshold curves are presented in Supplementary Fig. 15a-c, showing that the lasing threshold is around 200 µ J mm −2 .
outlook
We have demonstrated the use of a laser-emission-based imaging tool (LEM) that takes advantage of the high intensity, high background suppression and high spectral/spatial resolution of laser emission. We tested its validity in early-stage cancer diagnosis and in the evaluation of various nuclear biomarkers (nucleic acids, EGFR, p53 and Bcl-2) in human cancer tissues, which may benefit current clinical practice by providing complementary information that is difficult or impossible to obtain using conventional H&E, IHC and IF methods. We discuss a few possible areas that may benefit from the use of the LEM: (1) The use of conventional H&E, IHC and IF involves subjectivity, and may lead to significant variations in tissue evaluation by pathologists [22] [23] [24] 54 . The LEM can potentially provide a means to quantify the number of sites within a cell that have different levels of biomarker expression and the number of cells that express high nuclear biomarkers. In Fig. 5 , each lasing cell was counted only once, even though there might be multiple lasing stars present inside the lasing cell. Despite this significantly simplified way of categorization, the LEM is already able to distinguish cancer and normal tissues. On the other hand, we have discussed that the lasing stars in cancer tissues may have different lasing thresholds due to different biomarker concentrations. By increasing the pump energy density, the histogram of the lasing stars with different thresholds can be constructed, which may allow subcategorization of the cancer tissue (for example, in terms of severity and sensitivity to therapies); (2) Through LEM we found that multiple sites having high biomarker expression exist within a nucleus. Further work is needed to elucidate mechanisms of the occurrence of those spots, and how to make use of them in cancer diagnosis/prognosis; (3) In addition to cancer cells, the same technology can be extended to stroma cells (cancer-associated fibroblasts) that overexpress biomarkers. Supplementary Fig. 16 gives a lasing example of a colon tissue expressing Bcl-2. Recent reports have revealed that the interaction between stromal cells and tumour cells plays a major role in cancer growth and progression 55 . Moreover, stromal gene expression has also been shown to define poor-prognosis subtypes in several cancers 56, 57 . Therefore, the capability to observe tumour stroma lasing will be of potential significance to predict clinical outcomes and strengthen clinical prognostic factors; (4) Other potential applications can also be explored, including Pap smear stain examination, intraoperative image-guided neurosurgery and tumour resection, and fluorescence in-site hybridization (FISH); (5) Although dual detection (two-plexed detection) was achieved in this work, the LEM is capable of accommodating more fluorophores. For instance, in Supplementary Fig. 17a lasing emission from a third dye (high-affinity nucleic acid dye, SYTOX Blue) was achieved, which is centred on 500 nm with a bandwidth less than 5 nm. Furthermore, we have shown that at least four lasing-emission wavelengths can be clearly distinguished within the range of 500-550 nm ( Supplementary Fig. 17b ). High-wavelength multiplexicity of the lasing emission should now be explored for better characterization of cells and tissues; (6) The laser output from tissues provides a number of optical parameters that are not seen in fluorescence, such as the lasing threshold of various biomarkers, the spatial distribution of the lasing mode, lasing-mode competition and lasing-gain clamping. Further work is needed to understand how those parameters reflect the underlying biological and physiological processes of cancerous tissues, and to achieve better spectral and spatial resolution. methods Tissue and device preparation. A total of 41 tissue samples (N = 41) from 35 patients were used, including human lung tissues (N = 38, labelled as P1-P32) and human colon tissues (N = 3, P33-P35). In particular, P18-P20 are identified as early-stage lung cancer samples. All the human lung and colon tissues were purchased from OriGene Technologies in the form of OCT (optimal cutting temperature) frozen tissue blocks. Both male and female patients diagnosed with stage I/II cancer, aged 46-78, were examined. All human subjects are fully informed and are explicitly asked for their consent to future research use of their samples. Samples are collected from a diverse set of medical institutions throughout the United States to maximize patient diversity. Those tissues were verified at OriGene by pathologists with full pathological evaluation data, clinical annotation (including patient age, gender and minimum stage grouping), abstracted pathology reports to ensure the accuracy of the sample level diagnosis (that is, a normal adjacent sample collected from a cancer patient) and details of the sample's cellularity (% normal cells, % lesion cells, % tumour cells, % stroma and % necrosis). For the exemplary tissues used in Fig. 8 , both tissues were examined by pathologists and verified with lung adenocarcinoma and EGFR.
On receipt, all OCT tissue blocks were sliced into 15 μ m thick sections by using a cryostat (Leica 3050S). The selected tissue section was picked up and placed on the top of a poly-l-lysine (Sigma-Aldrich no. P8920) coated dielectric mirror, which was first cleaned and rinsed with lysine for better tissue adhesion. The tissue were then rinsed with PBS (phosphate buffered solution, ThermoFisher no. 10010023) and air dried before staining/labeling (see staining/labelling details in the next section). Finally, the tissue was covered by the top dielectric mirror. For confocal IF microscopy, the tissue was first deposited on the top of a superfrost glass slide (ThermoFisher no. 3021-002), followed by the same staining process, and then mounted with Fluoromount (Sigma-Aldrich no. 4680) and covered with a coverslip before scanning.
For experiments in Fig. 4 , all tissues were first examined with H&E histopathology slides to select the area that consists of all tumour cells or all normal cells (as shown in Supplementary Fig. 7 ). All of the tissues were sectioned into 4 slices and at least 5 cells within the tumour/normal region from each tissue section were randomly selected and measured.
Staining and labelling. For IHC staining, the tissue was fixed on a superfrost glass slide (ThermoScientific no. 15-188-48) by immersing in pre-cooled acetone (− 20 °C) for 3 min and dried off at room temperature. The slide was then rinsed with PBS twice. Next, the tissue was first blocked with BSA (bovine serum albumin) buffer for 10 min to prevent non-specific binding and rinsed with PBS thoroughly. Then the tissue was incubated with 200 µ l of diluted primary antibody (anti-human-EGFR antibody (Abcam no. 52894)) overnight at 4 °C. The primary antibody was prepared at 1:50 solution, with a final concentration of 0.005 mg ml −1 . After incubation of primary antibodies, the tissue was rinsed with PBS, followed by 30 min of staining with HRP-conjugated anti-Rb IgG secondary antibody (Abcam no. 6721) at room temperature at a dilution of 1:200 (final concentration = 0.01 mg ml −1 ). Then DAB substrate solution (Abcam no. 64238) was applied to the tissue for 5 min to reveal the colour of the antibody staining. After rinsing 5 times, the tissue was dehydrated with pure alcohol, then mounted with mounting medium (Abcam no. ab64230), and finally covered with a coverslip. The same procedure was applied to both lung and colon tissues. For colon tissues, two additional primary antibodies, anti-mutant p53 (Abcam #32049) and anti-Bcl-2 (Abcam no. 182858), were used.
For nucleic acid labelling, YOPRO solution (ThermoFisher no. Y3603) was dissolved in PBS at a concentration of 0.5 mM, then diluted to lower concentrations with PBS. The prepared YOPRO solution was then applied to the tissue sections for 10 min and rinsed with PBS solution three times before measurements. The above process was the same for both IF and laser measurements.
For antibody-fluorophore labelling of lung tissues, the glass slide was first rinsed with PBS twice and blocked with BSA buffer for 10 min to prevent nonspecific binding, then rinsed again with PBS. Next, the tissue was incubated with 200 µ l of diluted primary antibody (anti-human-EGFR antibody (Abcam no. 52894)) overnight at 4 °C. The primary antibody was prepared at 1:50 solution, with a final concentration at 0.01 mg ml −1 . After incubation with primary antibodies, the tissue was rinsed with PBS thoroughly, followed by FITC conjugated anti-Rb IgG secondary antibody (stained for 2 hours at room temperature). The secondary antibody (ThermoFisher no. 65-6111) was prepared at 1:5 dilution to reach the final concentration of 0.2 mg ml −1 . Finally, the tissue was rinsed again with PBS before the laser experiment. The same procedure was applied to colon tissues, in which the primary antibodies anti-EGFR antibody (Abcam no. 52894), anti-mutant p53 antibody (Abcam no. 32049) and anti-Bcl-2 antibody (Abcam no. 182858) were used, followed by FITC-conjugated anti-Rb IgG secondary antibody (stained for 2 hours at Nature Biomedical eNgiNeeriNg room temperature). The above process was the same for both IF and laser measurements.
For dual staining of anti-EGFR-FITC and YOPRO, we first applied anti-EGFR-FITC (the same procedure as described for primary and secondary antibody labelling) to the lung tissue sections, then 0.1 mM YOPRO solution was applied for 20 min to the same tissue and rinsed with PBS solution twice before measurement. For staining of SYTOX Blue (ThermoFisher no. S11348) and BOBO-1 iodide (ThermoFisher no. B3582) in Supplementary Fig. 17 , SYTOX and BOBO-1 iodide were dissolved in PBS at a concentration of 0.2 mM, following by the same staining procedures as for YOPRO.
Optical imaging techniques and LEM setup. The bright-field IHC images were taken with a Nikon-E800 Wide-Field Microscope. The confocal fluorescence microscopic images were taken by using Nikon A1 Spectral Confocal Microscope with a laser source with an excitation of 488 nm. The bright-field images as well as the video (Supplementary Video 1) of the laser emissions ('lasing stars') in tissues were captured using a CCD (Thorlabs no. DCU223C) integrated directly on top of the objective in our experimental setup (see Supplementary Fig. 2a for details) . In particular, the fluorescence images in Supplementary Fig. 5 were first captured with a wide-field fluorescence microscope (without the top mirror), then the corresponding lasing measurements were immediately performed by covering the tissue samples with the top mirror.
A typical confocal setup was used to excite the sample and collect emission light from the FP cavity (see the optical setup in Supplementary Fig. 2a ). A pulsed OPO laser (pulse width: 5 ns, repetition rate: 20 Hz) at 465 nm was used to excite the stained tissues. The FWHM of the focused laser beam size was ~30 μ m in diameter, in which the spatial sampling area is slightly larger than the focal beam size. The pump energy density was adjusted by a continuously variable neutral density filter, normally in the range of 1− 200 μ J mm −2 . The emission light was collected through the same objective, then separated by a beam splitter to the spectrometer (Horiba iHR550, spectral resolution ~0.2 nm) and CCD for spectral and image analysis.
The laser-emission scanned images were collected through the same optical setup, in which the images were taken by the CCD (10 fps, Thorlabs no. DCU223C) mounted on top of the objective (NA 0.42, 20× ). The raster scanning stage was home-built using two linear actuators with electric controllers (Newport, no. CONEX TRA25CC) and integrated with a raspberry PI/touchscreen (Digikey no. 8997466) for operation. The LEM images shown in Figs. 5-7 (fieldof-view of 150 × 150 μ m per frame in this study) was formed by mapping and integration of 25 individual CCD images (30 × 30 μ m). However, a larger mapping area up to 1 × 1 mm is achievable with the aid of algorithms. Currently the accuracy of the stage is limited by 3 μ m during each displacement.
FP microcavities. The FP microcavity was formed by two customized dielectric mirrors ( Supplementary Fig. 2 ). The top mirror (made by Qingdao Novel Beam Technology Co., China) had a high reflectivity in the spectral range of 520-555 nm to provide optical feedback and high transmission around 465 nm for the pump light to pass through, whereas the bottom mirror (made by Evaporated Coating, USA) had a slightly wider reflection band. The respective reflectivity for the top mirror and bottom mirror at the lasing wavelength (535-555 nm) is approximately 99.8% and 99.9%, respectively, while the transmission of the top mirror at pump wavelength (465 nm) is ~90.2%. The Q-factor for the FP cavity was on the order of 10 4 , at a cavity length of 15 μ m (without tissues). Details of the fabrication and characterization of the FP cavities have been described previously 58 .
Data availability. The authors declare that all data supporting the findings of this study are available within the paper and its Supplementary Information. All raw images and data generated in this work, including the representative images provided in the manuscript, are available from the corresponding author upon request. Corresponding author(s): Xudong Fan
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Experimental design 1. Sample size
Describe how sample size was determined. A total of 41 tissue samples (N=41) from 35 biopsies from human patients were used in this study. For Fig.4 , at least 20 cells from each of 14 patients (N=20) were tested. In Figs. 5-6, 11 tissue samples from patients (both cancer and normal tissues) were used. 5 tissue sections were selected from each patient. In Figs. 7-8, 12 samples from patients were used. In SFig. 14, 3 patients with colon cancer were tested (N=3).
Data exclusions
Describe any data exclusions. All cancer and normal tissues were first examined by pathologists before experiments. We did not include or exclude any particular tissue samples. (See Methods section for Tissue and device preparation).
Replication
Describe whether the experimental findings were reliably reproduced.
Our worked showed high reproducibility. Different cancer/normal tissues were tested over 100 tissue sections, and the data analysis was very reliable.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Patient samples were mainly divided into two groups, cancer and normal. In particular, we have used mostly cancer tissues from stage I/II based on the scope of this paper. All tissue samples from patients were selected randomly across different ages and gender.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Researchers were not blinded to cancer/normal samples. All tissues were diagnosed by pathologists with IHC/H&E as the golden standard before LEM measurements.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
The T test were done with Origin lab.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All materials used in this work are commercially available.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
